Advertisement

Poor Quality Pharmaceuticals in Global Public Health

  • Satoru Kimura
  • Yasuhide Nakamura
Book

Part of the Trust book series (TRUST, volume 5)

Table of contents

  1. Front Matter
    Pages i-xxiii
  2. Satoru Kimura, Yasuhide Nakamura
    Pages 1-24
  3. Pharmaceuticals in Globalization

    1. Front Matter
      Pages 25-25
    2. Satoru Kimura, Yasuhide Nakamura
      Pages 63-68
    3. Satoru Kimura, Yasuhide Nakamura
      Pages 69-89
    4. Satoru Kimura, Yasuhide Nakamura
      Pages 91-100
    5. Satoru Kimura, Yasuhide Nakamura
      Pages 101-116
  4. Market and Access in Local Aspects

    1. Front Matter
      Pages 117-117
    2. Satoru Kimura, Yasuhide Nakamura
      Pages 119-147
    3. Satoru Kimura, Yasuhide Nakamura
      Pages 149-167
    4. Satoru Kimura, Yasuhide Nakamura
      Pages 169-184
    5. Satoru Kimura, Yasuhide Nakamura
      Pages 185-212
    6. Satoru Kimura, Yasuhide Nakamura
      Pages 213-216

About this book

Introduction

This book aims to clarify the global aspects of poor quality pharmaceuticals, generic products in particular, becoming complicated through the process of IMPACT (International Medical Products Anti-Counterfeiting Taskforce) organized by the initiative of the World Health Organization (WHO) in 2006. The findings from this book provide a long-term perspective to policymakers. This book discusses from the following points: industrial standardization, healthcare market accessibility, motivation on supply side, WHO medicines policy and intellectual property rights. Standardization regulates the quality and enabled the generic medicines spreading to developing/emerging countries through technology transfer. However, quality is a part of cost and reflected to price. When a healthcare service market is divided according to wealth gap, compliance to standardization for quality on supply side is divided accordingly. Thus, poor quality pharmaceuticals are prevalent worldwide. Generic pharmaceuticals are essential resources in public health. The WHO has been involved in the dispute around the intellectual property rights under its intention to promote the new drug development for neglected diseases. Global pandemic of AIDs is a critical factor to accelerate the confusion. This created feelings of distrust among developing/emerging countries against developed countries if the WHO was in favour of developed countries. In addition to that, an easy and optimistic start of IMPACT stirred up conflicts of interests in the international community. The problem of poor quality pharmaceuticals became more complicated through the conflicts on intellectual property rights; patented drugs to generic drugs. A key for quality generic products is the formation of a single healthcare service market where good motivation on supply side together with fair competitiveness with patented pharmaceuticals and equitable access to services (both for the rich and the poor) are ensured. Political commitment to investment and regulatory infrastructure for the market is crucial.

Keywords

Quality of pharmaceuticals WHO IMPACT counterfeit drugs drug quality Intellectual property rights

Authors and affiliations

  • Satoru Kimura
    • 1
  • Yasuhide Nakamura
    • 2
  1. 1.Department of Reference StandardsPharmaceutical and Device Regulatory Science Society of JapanOsakaJapan
  2. 2.School of Nursing and RehabilitationKonan Women's UniversityKobeJapan

Bibliographic information

  • DOI https://doi.org/10.1007/978-981-15-2089-1
  • Copyright Information Springer Nature Singapore Pte Ltd. 2020
  • Publisher Name Springer, Singapore
  • eBook Packages Social Sciences
  • Print ISBN 978-981-15-2088-4
  • Online ISBN 978-981-15-2089-1
  • Series Print ISSN 2509-7679
  • Series Online ISSN 2509-7903
  • Buy this book on publisher's site